Skip to main content

Sign up for our newsletter.

Quality journalism. Progressive values. Direct to your inbox.

"It is highly unlikely that a pharmaceutical company executive who has made passionate arguments against price restraints is going to advance real reform," said Robert Weissman, president of Public Citizen. (Photo: Worldwide Speakers Group)

Warnings of 'Big Pharma Coup' as Trump Considers Drug Exec. for Health Secretary

"Trump has decided to cut out the middleman, and let a pharmaceutical executive literally run the health department."

Jake Johnson

With media reports indicating that President Donald Trump is leaning toward selecting former pharmaceutical industry executive Alex Azar to head the Department of Health and Human Services (HHS), the consumer advocacy group Public Citizen warned in a statement Wednesday that Azar's appointment would essentially complete "Big Pharma's coup of the healthcare sphere."

"Just days after denouncing 'out-of-control' drug prices, President Donald Trump appears set to show he doesn't mean it by naming a former pharmaceutical company executive to run the U.S. Department of Health and Human Services,"
—Robert Weissman, Public Citizen
"Just days after denouncing 'out-of-control' drug prices, President Donald Trump appears set to show he doesn't mean it by naming a former pharmaceutical company executive to run the U.S. Department of Health and Human Services," said Public Citizen president Robert Weissman. "In his public statements, Alex Azar has made clear that he is opposed to measures to restrain drug company profiteering and limit improper marketing and favors weaker drug safety approval standards."

Azar spent a decade as an executive with the pharma giant Eli Lilly, where he directed the company's sales operations. Before joining Eli Lilly, Azar served as deputy secretary of the HHS under George W. Bush.

As Politico reports, Azar also happens to be "one of the many drug industry executives" who contributed to Trump's presidential campaign—a fact that runs counter to the president's frequent criticism of elected officials who take cash from pharma executives.

If nominated, Azar would be filling the role left vacant by Tom Price, who resigned last month amid growing outrage over his use of private jets to travel across the U.S. on government business.

Weissman argued on Wednesday that while Price was a supporter of the pharmaceutical industry, Azar would take Big Pharma's influence on American healthcare to the next level.

"The swamp only gets worse," Weisman said. "Trump has decided to cut out the middleman, and let a pharmaceutical executive literally run the health department."

Weissman concluded that Azar's nomination would effectively foreclose the possibility of any substantive steps toward tackling high drug prices or pharma monopolies.

"Americans understand, passionately, that drug company price gouging leads to rationing of care. It is unethical and must end," Weissman said. "But it is highly unlikely that a pharmaceutical company executive who has made passionate arguments against price restraints is going to advance real reform."


Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.

... We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.

Critics Warn Biden 'Summit for Democracy' Will Highlight Democrats' Failures at Home

"President Biden can't champion democracy across the globe without fulfilling his promise to protect our voting rights at home."

Jessica Corbett ·


'Like a Teenager Promising to Clean Their Room in 30 Years': Biden Net-Zero Climate Goal for 2050 Ridiculed

"2050 is an extremely weak goal for the federal government to free itself from climate-heating pollution. It ignores existing technology and adds decades to GSA's own commitment to 100% renewable energy by 2025."

Brett Wilkins ·


Biden Should Cancel Student Debt or Watch $85 Billion Evaporate From US Economy: Analysis

Far-reaching cancellation enacted by Biden could add more than $173 billion to the nation's GDP in 2022 alone.

Kenny Stancil ·


Given Cover by Red-Baiting GOP, Corporate Dems Rebuked for Tanking Biden Nominee for Top Bank Regulator

"If you think that Senate Democrats rose up to [Republicans'] shameful display of modern McCarthyism by rallying around President Biden's nominee or her ideas that banking should work for the middle class, then you don't know the soul of today's Democratic Party," wrote one columnist.

Julia Conley ·


'S.O.S.!': Groups in Red States Nationwide Plead With Democrats to Pass Voting Rights Bill

"We can tell you firsthand that our Republican senators have no interest in joining this effort."

Jake Johnson ·

Support our work.

We are independent, non-profit, advertising-free and 100% reader supported.

Subscribe to our newsletter.

Quality journalism. Progressive values.
Direct to your inbox.

Subscribe to our Newsletter.


Common Dreams, Inc. Founded 1997. Registered 501(c3) Non-Profit | Privacy Policy
Common Dreams Logo